MiSight® 1 Day:
FDA-Approved Myopia Control

MiSight 1 day is the only FDA-approved soft contact lens for myopia control in children. Here's what the evidence actually shows — including the 6-year follow-up data most summaries leave out.

55%

Axial length reduction vs control at 3-year endpoint (Chamberlain 2019)

59%

Axial length reduction at 6-year endpoint (Chamberlain 2022)

age 8+

FDA approval age — youngest approved myopia control CL

What is MiSight 1 Day?

MiSight 1 day (CooperVision) is a daily disposable soft contact lens with a dual-focus (DF) optical design. It uses concentric zones alternating between distance correction and treatment zones that create myopic defocus in the peripheral retina — which is thought to slow axial elongation by reducing the growth signal to the posterior eye.

In 2019 it became the first contact lens to receive FDA approval specifically for slowing the progression of myopia in children aged 8–12 at initiation of treatment.

Clinical evidence: the Chamberlain trials

3-year RCT (Chamberlain et al. 2019)

The pivotal trial enrolled 135 children aged 8–12, randomised to MiSight or single-vision daily disposables. At 3 years:

Axial elongation reduced by 55% vs control (0.30mm vs 0.67mm)
Refractive progression reduced by 52% (−0.51D vs −1.09D)
No serious adverse events reported; microbial keratitis rate 0%

6-year follow-up (Chamberlain et al. 2022)

The 6-year data — where control participants crossed over to MiSight at year 3 — showed that children who started MiSight earlier maintained a cumulative AL advantage even after the control group switched. The early-start group ended with ~0.4mm less axial elongation than the delayed-start group at 6 years, demonstrating a persistent benefit of early initiation.

Key clinical takeaway: The 6-year data support starting treatment earlier rather than waiting. The AL advantage gained in years 1–3 is not fully recovered by the delayed-start group even after 3 additional years on the lens. This supports the IMI 2025 recommendation to treat at diagnosis rather than waiting for fast progression.

Mechanism: how it slows axial elongation

MiSight uses a patented ActivControl® Technology with two treatment zones and two correction zones in concentric rings. The treatment zones create myopic defocus on the peripheral retina — imposing a "stop signal" on axial elongation. Central vision is fully corrected by the correction zones.

Patient selection criteria

Factor	Suitable	Consider alternative
Age	≥8 years (FDA approval)	<8 years → spectacle lenses
Prescription	−0.75D to −4.00D (−0.75D to −0.50D cyl)	High cylinder, high myopia
Compliance	Child motivated, parent supportive	Reluctant to handle lenses
Lifestyle	Active, sports, no glasses preferred	Strong glasses preference
Ocular health	Healthy anterior segment	Recurrent blepharitis, dry eye

What to tell parents

MiSight slows how fast myopia gets worse — it does not cure or reverse it
The lens is worn daily and discarded each night (no overnight wear)
FDA approval means it has been reviewed for both safety and myopia control efficacy — it is not just a regular soft lens
Compliance matters: the 55% efficacy assumes full-time wear as a contact lens
If discontinued, there is some evidence of rebound; clinical consensus is to continue until progression has stabilised (typically late teens)

⚠ Rebound on discontinuation: IMI 2025 notes limited data on MiSight discontinuation rebound, but the general principle that axial elongation may accelerate on stopping any myopia control treatment applies. Discontinuation decisions should be made with the clinician.

MiSight vs Stellest — when to choose which

Both MiSight and Stellest® have strong RCT evidence and are first-line options. The choice depends primarily on age, lifestyle, and compliance profile:

Choose MiSight when the child is ≥8, willing to handle lenses daily, active in sports, or prefers glasses-free daytime vision
Choose Stellest® when the child is <8, not ready for contact lenses, or has difficulty with compliance pressure of daily wear
Combination therapy (MiSight + low-dose atropine) for high-risk patients with rapid progression

See the full MiSight® vs Stellest® comparison →

Comparison

MiSight® vs Stellest® — Deep Dive

Head-to-head RCT data, mechanism, patient selection, and prescribing guidance.

All Treatments

All 9 Treatments Ranked

MiSight in context — every myopia control modality compared by efficacy.

Combination

Add Atropine to MiSight?

Dose comparison and combination therapy evidence for high-risk patients.

Timing

When Should Treatment Start?

IMI 2025 treatment triggers — age, AL percentile, growth velocity.

Rankings

Best Myopia Treatments (2026)

All modalities ranked with RCT source for each efficacy figure.

Calculator

Project MiSight Outcomes

See projected AL at 18 with MiSight vs no treatment for your patient.

Project MiSight outcomes for your patient

Enter age + axial length. See MiSight projected against all other modalities, side by side. Free, no login.

Open Calculator →

No signup · No credit card · 30 seconds

Chamberlain P et al. A 3-year randomized clinical trial of MiSight lenses for myopia control. Optom Vis Sci. 2019;96(8):556–567 · Chamberlain P et al. Myopia progression on discontinuation of myopia control lenses in children. Optom Vis Sci. 2022;99(2):82–89 · IMI 2025 Digest (Tahhan N et al.) · MiSight® is a registered trademark of The Cooper Companies, Inc. This page is educational — not a prescribing recommendation.

MiSight® 1 Day:FDA-Approved Myopia Control